Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

MLA

Shah, Saumya M., et al. “Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.” American Journal of Ophthalmology, vol. 243, Nov. 2022, pp. 98–108. EBSCOhost, https://doi.org/10.1016/j.ajo.2022.07.025.

APA

Shah, S. M., Boopathiraj, N., Starr, M. R., Dalvin, L. A., AbouChehade, J., Damento, G., Garcia, M. D., Hodge, D. O., Bakri, S. J., Sit, A. J., & Iezzi, R. (2022). Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. American Journal of Ophthalmology, 243, 98–108. https://doi.org/10.1016/j.ajo.2022.07.025

Chicago

Shah, Saumya M, Nithya Boopathiraj, Matthew R Starr, Lauren A Dalvin, Jackson AbouChehade, Gena Damento, Maria D Garcia, et al. 2022. “Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.” American Journal of Ophthalmology 243 (November): 98–108. doi:10.1016/j.ajo.2022.07.025.